2022 亞洲生技大展 國家衛生研究院 推廣技術簡介
最新技術
摘要 (Abstract)
本發明將體積大、笨重、使用局限的治療用超音波器材做成輕巧、便利、可居家使用的裝置，透過手機的特定APP經有線或無線藍牙方式控制超音波驅動電路，產生不同參數的超音波，運用在痠痛舒緩、神經調節、復健、生醫研究等場域。
The invention is a wearable ultrasonic device controlled by the smart cell phone or the portable instrument. The wearable ultrasonic device is light-weight, user-friendly and home-use. Different ultrasonic doses can be set and generated by the custom APP software via wire or wireless Bluetooth method. Applications of the invention are pain management, neuromodulation, rehabilitation, biomedical research and so forth.
摘要 (Abstract)
此技術提供與持續使用鴉片類藥物、K他命、苯丙胺和酒精等物質的患者合併不同狀態的血漿生物標誌物。這些狀態包括患有愛滋病毒或C型肝炎病毒感染的患者，或持續使用海洛因或K他命，或慢性壓力的嚴重程度，或慢性多種物質使用造成的神經毒性等。這些診斷指標可以幫助患者或護理人員監控這些狀態，以了解可能有利於患者改善之治療。
This technology is providing the plasma biomarkers relating to different status of a patient who was constantly using substances, including opioid, ketamine, amphetamine, and alcohol. These statuses include of a patient who had HIV or HCV infection, or continual of heroin or ketamine substance use, or the severity of chronic stress, or neurotoxicity prognosis after chronic multiple substance use disorder. These diagnosis indicators may help the patients or the care-giver to monitor these statuses in order to learn the current treatment might be beneficial to a patient’s improvement.
摘要 (Abstract)
本案所開發的CpG-2722寡脫氧核苷酸，可誘發TLR9-活化免疫反應及/或一種TLR-21-活化免疫反應，在人與不同的物種中均有良好的免疫調節力。醫學方面的應用包括，作為細胞(如樹突狀細胞等)冶療的免疫調節劑，癌症冶療葯物的合併使用劑，以及人或動物用疫苗佐劑。
1. The CpG-2722 oligodeoxynucleotide, an immunogenic composition, developed in this invention relates to inducing a TLR9 activated immune response and/or a TLR21 activated immune response. TLR9 is expressed in mammalian species. TLR21 is expressed in avian species. Fishes contain both TLR9 and TLR21. Current used CpG-ODN usually have species-specific activity and designed by targeting TLR9, therefore may not be able to be used for multiple species. CpG-2722 we developed has good immune stimulatory activity on human. It also has high activity on many other commercially raised animals such as fish species, avian species, and other mammalian species.
2. Medical applications of this CpG-2722 include used as immunomodulators for cell (such as dendritic cells) therapy, combinational use with other chemotherapy drugs or immune checkpoint inhibitors for cancer therapy, and used as vaccine adjuvants for different infectious diseases.
摘要 (Abstract)
此技術是以癌細胞釋放致癌代謝物琥珀酸作為癌症診斷生物標誌物和單克隆琥珀酸抗體作為抗癌治療性抗體。已開發出humanized單克隆琥珀酸抗體為抗癌代謝抗體，其可抑制巨噬細胞極化成TAM與腫瘤轉移，並提高腫瘤老鼠的存活率。
This technology uses cancer cells derived secreted carcinogenic metabolite succinate as a cancer diagnostic biomarker and promising targets for the development of anti-cancer monoclonal antibodies. Humanized monoclonal succinate antibody has been developed as an anti-cancer metabolic antibody, which can inhibit the polarization of macrophages into TAM and tumor metastasis, and improve the survival rate of tumor mice.
更多精選
技術摘要（中文）
本發明為藉由 mu 鴉片受體的變構調節劑，使原本是拮抗劑的 naloxone 變為促效劑，使其在活體中產生止痛效果。目前已有化合物在小鼠模式中具有上述特性，未來有機會開發新型的強效止痛劑。
技術摘要（英文）
The invention disclosed a concept that a small molecule could inverse mu-opioid receptor antagonist, naloxone, to agonist and exhibited analgesic effect in vivo. Presently, there is a small molecule exhibited the effect described above in a mice model, and this concept can be applied to develop new analgesics.
智權狀態：中華民國(TW I625120)、美國(US)、日本(JP)、中國(CN)、歐洲(EP)、加拿大(CA)
技術摘要（中文）
目前所發展的一系列氨基噻唑化合物(Aminothiazole compounds)為多重激酶抑制劑，初步的結果顯示，此化合物對於ABL1、FLT3、c-KIT、PDGFR、RET、SRC、VEGFR等激酶及其區域突變都有不錯的抑制效果(IC50 < 100 nM)。此外此類化合物對於c-KIT突變型之胃腸道基質瘤(Gastrointestinal Stromal Tumors，GIST)細胞株及FLT3突變型相關之急性骨髓性白血病(Acute Myeloid Leukemia，AML)細胞株都有很好的生長抑制效果。基於上述之説明，此類噻唑系列化合物有機會發展出更新一代的藥物，能有效的治療GIST與AML患者，以及解決因c-KIT或其他酪氨酸激酶突變(如FLT3)所產生抗藥性的問題。
技術摘要（英文）
We have identified a series of Aminothiazole compounds, multi-targeted tyrosine kinase inhibitors. The preliminary kinase profiling of these compounds showed strong inhibition of ABL, FLT3, c-KIT RET, PDGFR, SRC and VEGFR, an activity spectrum similar to tyrosine kinases-targeted drugs on the market. We found this series of compounds exhibited good anti-proliferative response to c-KIT mutant gastrointestinal stromal tumors (GIST) cells and FLT3 driven acute myeloid leukemia (AML), particularly AC220-resistant leukemia cells in vitro. In addition, these thiazole compounds showed potent inhibitory activity on c-KIT phosphorylation in mutant GIST430 cells than the other agents, including imatinib, sunitinb, nilotinib and regorafinib. These results inspired us to further develop these compounds and to identify a novel “Best in Class” anticancer drug that is orally active against drug resistant human GIST and AML in patients.
智權狀態：中華民國(TW I620748)、美國(US)、日本(JP)、中國(CN)、歐洲(EP)、韓國(KR)
技術摘要（中文）
本發明揭示一種可植入性神經再生導管及其製造方法。可植入性神經再生導管主要包含一生物可分解性聚合物及一金屬。此外，導管亦可包含一或多種神經再生促進成分，其包含生物活性成分或細胞。導管之內表面可進行微圖案化微影製程以形成促使細胞排列生長之微溝槽。
技術摘要（英文）
Implantable nerve regeneration conduits and methods of making the same are disclosed. The implantable nerve regeneration conduits mainly comprise a biodegradable polymer and a metal. Moreover, the conduits may also comprise one or more nerve regeneration enhancing elements, which comprise bioactive molecules or cells. The inner surface of the conduits may be micropatterned photolithographic processes to form microgrooves for facilitating cell alignment.
智權狀態：中華民國(TW I414328)、美國(US)
技術摘要（中文）
一種為了登革熱病毒之四種血清型之包膜蛋白第三區塊而設計的共有胜肽序列，其可用於對抗登革熱病毒之多種血清型的疫苗中。該疫苗能夠誘發中和抗體反應，對抗多種血清型之登革熱病毒。
技術摘要（英文）
A consensus peptide sequence designed for domain III of the envelope proteins of four serotypes of dengue virus and used in a vaccine against multiple serotypes of dengue virus. The vaccine is able to elicit cross-neutralization antibody responses against multiple serotypes of dengue virus.
智權狀態：中華民國(TW I445547)、美國(US)
技術摘要（中文）
本發明之特徵在於提供一種新穎的PEI-co-PEGs(Polyethylenimine-co-Poly(ethylene glycol))化合物(簡稱LPEI-co-PEGs)，可用於核酸傳送(nucleic acid delivery)中作為載體。該化合物對細胞具有低毒性(toxicity)，不易發生發炎反應或是使細胞壞死；且對核酸具有高傳遞效率(delivery efficiency)、高釋放效率(releasing efficiency)，可作為良好的核酸載體。此外該化合物可發出螢光，因此還可用於細胞即時影像(intracellular imaging)技術中。
技術摘要（英文）
The invention provides a novel, highly biocompatible and linear-like polyethylenimine-co-poly(ethylene glycol) (hereafter called LPEI-co PEG) as a nucleic acid vector. The polymers can prevent nucleic acid from degradation while entering the cells, and furthermore, the polymer has enhanced releasing efficiency after entering the cells. It can be a good vector in nucleic acid delivery since it is nontoxic and shows excellent performance in nucleic protection and gene silencing experiment. In addition, we have observed that the LPEI-co-PEG can emit green photoluminescence, therefore the LPEI-co-PEGs can also be used in intracellular imaging.
智權狀態：中華民國(TW I426085)及美國(US)
技術摘要（中文）
白血球沾黏因子在許多發炎疾病中及調控發炎機轉上扮演重要角色。我們結合了三種不同影像報導基因，包括利用螢火蟲冷光酵素、綠螢光蛋白、以及第一型單純疱疹病毒胸腺嘧啶激酶，並且利用白血球沾黏因子啟動子來驅動基因轉殖載體，並且產出基因轉殖動物。我們利用各成像系統相對應之探針，成功檢視基因轉殖動物內之個別影像基因表達結果，具有多重影像報導基因之基因轉殖動物模型，結合了原本屬於各種影像成像系統之優勢，更能同時運用多種成像系統來觀測並互相驗證，具有多重影像報導基因之動物可以應用於追蹤細胞之增生、分化、遷移、以及發展之機制及過程，並利用”白血球沾黏因子啟動子驅動多重影像報導基因動物”證明其可成為發炎報導動物模型，可以非侵入式觀察深層組織發炎狀態。
技術摘要（英文）
In this study, we developed transgenic mouse models in which the molecular imaging reporter expression was driven by 540-bp monocyte chemotactic protein 1 (CCL2) promoter region. MCP1 is known implicated in many diseases involving monocytic infiltrations. We have shown that the imaging reporter expression in animal or cells correlates to the tissue inflammation states. This specific transgenic mouse can be used as the reporting animals for deep tissue inflammation with broad applications. The potential applications include the detection of diseases that involve the change in MCP1 promoter activity, e.g. sepses, acute and chronic inflammation including all forms of granuloma, asthma, Alzheimer disease, rheumatoid arthritis, atherosclerosis, restenosis, and tumor angiogenesis. Therapeutic applications utilizing MCP1 as the targeting molecule and the anti-proliferation outcome of HSV1tK and synthetic substrates as the effector to treat the above illness.
智權狀態：中華民國(TW I418629)及美國(US)
技術摘要（中文）
CpG寡脫氧核苷酸是有效的免疫激活劑，己被開發作為不同物種的疫苗佐劑及免疫調節劑。本發明開發了一種新類型的CpG寡脫氧核苷酸，相較於目前己開發的CpG寡脫氧核苷酸，這類型的CpG寡脫氧核苷酸對兔子有較高的免疫激活力。與佛氏佐劑( Freund’s adjuvant) 相比較，這類包含約11-14個DNA基序的CpG寡脫氧核苷酸也有較強的佐劑效果以產生抗體反應，其毒性也較佛氏佐劑低，可用於兔子以作為疫苗及抗體生產的佐劑以及免疫調節劑，也可用於老鼠作為佐劑以利於單克隆抗体的生產。
技術摘要（英文）
CpG-oligodeoxynucleotides (CpG-ODN) has been developed as potent immune stimuli developed for using as adjuvant in different species. In this invention, TLR9 is the cellular receptor for CpG-ODN, and the CpG-ODN current developed has higher activity to rabbit TLR9 than Freund’s adjuvant and less toxicity as well. Here, a type of CpG-ODN containing a DNA sequence motif in about 11-14 deoxynucleotides has demonstrated to have potent immunostimulatory activity at least to rabbit TLR9, and capable of boosting a less toxic and potent antibody response in rabbits. It can also be used in mouse for monoclonal antibody production.
智權狀態：中華民國(TW I535451)、美國(US)、中國(CN)、香港(HK)
